Antihistamines are used as a first-line PROCEEDINGS THE VALUE OF A BROAD THERAPEUTIC INDEX FOR ANTIHISTAMINES * F. Estelle R. Simons, MD ABSTRACT
|
|
- Kristin Sharleen Thornton
- 5 years ago
- Views:
Transcription
1 THE VALUE OF A BROAD THERAPEUTIC INDEX FOR ANTIHISTAMINES * F. Estelle R. Simons, MD ABSTRACT The therapeutic index of a histamine-1 (H 1 )- antihistamine is the benefit-to-risk ratio of the medication and defines the range of doses and plasma concentrations over which the drug is effective and safe. In allergic rhinoconjunctivitis and urticaria, although the efficacy profiles of currently available H 1 -antihistamines are similar, these agents differ greatly with regard to safety, and this contributes to their different therapeutic indices. Compared with their first-generation predecessors, the orally administered second-generation H 1 -antihistamines such as cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine have fewer central nervous system (CNS) adverse effects. However, differences exist among second-generation H 1 -antihistamines in terms of their effect on the CNS, with some agents having potential for dose-related CNS effects when the manufacturer s recommended dose is exceeded. Similarly, in terms of cardiac safety, although all currently marketed H 1 -antihistamines are safer than astemizole or terfenadine, some of the medications in this class may be more likely than others to cause cardiac toxicity under certain circumstances. A broad therapeutic index is important not only when considering the potential *Based on a presentation given by Dr Simons at the XXI Congress of the European Academy of Allergology and Clinical Immunology. Address correspondence to: FER Simons, Department of Pediatrics & Child Health, University of Manitoba, 504D John Buhler Research Center, 727 McDermot Avenue, Winnipeg, Manitoba, Canada R3E 3P5. effects of concomitant administration of medications, herbal products, and foods on the H 1 -antihistamine bioavailability and efficacy, but also because patients may spontaneously increase their H 1 -antihistamine dose in order to obtain symptom relief. Fexofenadine is an example of an H 1 -antihistamine that has a broad therapeutic index beyond the manufacturer s recommended doses of 120 mg or 180 mg once daily. Fexofenadine has been shown to be effective at doses as low as 20 mg twice daily and to not cause sedation or cardiac toxicity at doses as high as 690 mg twice daily. (Advanced Studies in Medicine. 2002;2(24): ) Antihistamines are used as a first-line treatment for seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. The first-generation antihistamines, although effective in relieving the symptoms of rhinitis and urticaria, are associated with unwanted adverse effects such as sedation and impaired psychomotor function because of their lack of histamine-1 (H 1 )-receptor selectivity and, in particular, to their penetration into the central nervous system (CNS). Second-generation antihistamines were developed in the early 1980s with the aim of having greater specificity for the H 1 -receptor and less CNS penetration and, therefore, overcoming the adverse effects observed with older agents. Consequently, all of the currently available second-generation antihistamines exhibit broad therapeutic indices compared 872 Vol. 2, No. 24 November 2002
2 with their first-generation counterparts. However, the potential for CNS adverse effects still remain with some of these agents. Therefore, consideration of the therapeutic index when prescribing an antihistamine is more important than consideration of either efficacy or safety alone. This paper reviews the contributory factors involved in the evaluation of the therapeutic index of H 1 -antihistamines and focuses on the clinical relevance of a broad therapeutic index. THERAPEUTIC INDEX OF ANTIHISTAMINES The therapeutic index of an H 1 -antihistamine is the benefit-to-risk ratio, also referred to as the efficacy-to-safety ratio, of the medication. This ratio defines the range of doses and plasma concentrations over which the drug is effective and safe. The lower limit is determined by the minimally effective dose, which is the lowest dose, or lowest plasma concentration, associated with a beneficial clinical effect. The upper limit is determined by safety, which is the highest dose, or highest plasma concentration, tolerated without adverse pharmacologic effects. Most of the second-generation antihistamines have a more favorable therapeutic index than their predecessors because of their greater relative safety. First-generation antihistamines are still widely used, as indicated by the results of a recent telephone survey that included approximately 5000 individuals in communities across the United States. 1 The objective of the study was to obtain information on the use of all medications, including prescription drugs and over-the-counter medications, as well as vitamins and natural supplements, including herbal formulations, during the previous week. The survey showed that, of the 40 most commonly used drugs, the sedating H 1 -antihistamines diphenhydramine and chlorpheniramine were more commonly used than the nonsedating second-generation agents loratadine and fexofenadine, suggesting that further efforts are required to encourage patients and physicians alike to use the newer nonsedating H 1 - antihistamines. 1 In addition, the survey indicated that in any given week, most US adults take at least 1 prescription or nonprescription medication, including herbal formulations, and many people take multiple agents, raising concerns regarding potential drug-drug interactions that may occur. The differences among the newer antihistamines make evaluation of the therapeutic index an important consideration when prescribing these agents. The therapeutic index varies mainly according to the properties of the H 1 -antihistamine itself, and these differences are the focus of this review; however, it also depends on several other factors, such as the formulation (intranasal or oral), the disease (allergic rhinitis or urticaria), and the population (pediatric or geriatric) being treated. ACTIVITY OF ANTIHISTAMINES The activity of antihistamines has been determined using different in vitro and in vivo models. For example, measurement of H 1 -antihistamine concentrations in plasma and skin and correlation of those concentrations with their peripheral H 1 -receptor activity has been a useful tool for determining onset of action, relative potency, and duration of action as well as in developing optimal recommendations for the dose and dose frequency of individual agents. In a recent study, the extent of fexofenadine HCl (120 mg) and diphenhydramine (50 mg) distribution into the skin was examined, and the findings were related to peripheral H 1 -receptor antagonist activity. The investigators found that while the skin levels of fexofenadine correlated with H 1 -receptor activity, diphenhydramine neither penetrated the skin nor produced substantial H 1 -receptor activity. 2 In another study, comparative analysis of the effects of the second-generation H 1 -antihistamines, levocetirizine, ebastine, fexofenadine, and loratadine, showed that these agents were all effective in suppressing the histamine-induced wheal and flare response with levocetirizine exhibiting the greatest antihistaminic activity. 3 In addition, the efficacy profiles of H 1 -antihistamines have been established in numerous clinical studies. These studies have shown that, in general, the different H 1 -antihistamines have similar efficacy in the treatment of allergic rhinoconjunctivitis and urticaria. 4,5 For example, the H 1 -antihistamines, fexofenadine, loratadine, desloratadine, and cetirizine, have all proven to be effective for the treatment of allergic rhinitis and urticaria. 6-9 Furthermore, different doses of the same H 1 -antihistamines generally have similar efficacy profiles; that is, the dose-response curve is relatively flat. For example, when fexofenadine was administered to patients with chronic urticaria at doses of 20, 60, 120, and 240 mg twice daily, all doses significantly improved the mean total symptom score compared with placebo. 9 Advanced Studies in Medicine 873
3 SAFETY PROFILES OF ANTIHISTAMINES In contrast to their similar efficacy profiles, currently available H 1 -antihistamines differ greatly with regard to safety, and this is the factor that primarily contributes to their different therapeutic indices. A clean safety profile is particularly important for those patient populations at an increased risk for adverse effects, such as patients with a small body mass, hepatic or renal dysfunction, preexisting CNS or cardiac disorders, and in those using concomitant medications. EFFECTS ON CNS AND CARDIOTOXICITY First-generation H 1 -antihistamines such as diphenhydramine were associated with sedation and impairment, which is thought to have been a result of their ability to cross the blood-brain barrier and access CNS H 1 -receptors; therefore, these agents have a narrow therapeutic index. In contrast, orally administered second-generation H 1 -antihistamines, such as cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine, have fewer CNS adverse effects compared with their first-generation predecessors and therefore have wider therapeutic indices. The improvements in CNS effects with newer agents have been confirmed in more than 50 randomized, double-blind, placebo-controlled studies in which objective measurements of sleep, learning, memory, and psychomotor function have been made at regular intervals. 10 Although these drugs have improved features over first-generation antihistamines, second-generation H 1 -receptor antagonists differ from each other in terms of their CNS effects, and many of them have the potential for dose-related CNS effects when the manufacturer s recommended dose is exceeded. 10 An example of the differences in CNS effects between the antihistamines was shown in a recent postmarketing surveillance study assessing the sedative profiles of fexofenadine, loratadine, cetirizine, and acrivastine. In this study, although all 4 H 1 -antihistamines were associated with a low incidence of sedation, the incidence was lower with fexofenadine and loratadine than with cetirizine and acrivastine. 11 Fexofenadine is the only H 1 -antihistamine for which safety has been extensively assessed over a wide range of doses (Figure). 12,13 Consistent with other reports, a recent study by Hindmarch et al showed that fexofenadine HCl at a dose of 360 mg daily is demonstrably free from disruptive effects on aspects of psychomotor and cognitive function. 14 Furthermore, both qualitative and quantitative data from positron-emission tomography studies have shown that fexofenadine does not bind to the H 1 - receptor in the brain, suggesting that it does not cross the blood-brain barrier, thereby supporting the lack of sedation or impairment observed with this antihistamine in clinical studies. 15,16 Similarly, in terms of cardiac safety, although all currently marketed H 1 -antihistamines are relatively safe compared to astemizole or terfenadine, some of the medications in this class, such as diphenhydramine, may be more likely than others to cause cardiac toxicity under certain circumstances, such as when the manufacturer s recommended dose is greatly exceeded. 17 Because of the concerns regarding the car- Figure.The Range of Plasma Concentrations of Fexofenadine; Data for Which Safety Has Been Demonstrated 18 Mean Fexofenadine Plasma Concentration (ng/ml) mg 640 mg 480 mg 360 mg 280 mg 200 mg 130 mg 80 mg 40 mg 20 mg Time (h) Modified with permission from Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther. 1998;64(6): Vol. 2, No. 24 November 2002
4 diovascular safety of older agents, all newer agents are extensively studied to assess potential cardiotoxic effects. One of these agents, fexofenadine, was studied in controlled clinical trials involving more than 6000 patients. The findings showed that this medication does not cause QT c interval prolongation or cardiovascular side effects, including torsades de pointes. 12 DRUG-DRUG INTERACTIONS Absorption of H 1 -antihistamines from the gastrointestinal tract may be altered by concomitant administration of other agents. P-glycoprotein, a carrier protein that belongs to the superfamily of adenosine triphosphate (ATP)-binding cassette proteins, is involved in fexofenadine absorption. Inducers of this protein, such as grapefruit juice, decrease absorption, while inhibitors such as erythromycin or ketoconazole increase absorption. 19 Because fexofenadine has a broad therapeutic index, such effects are unlikely to be clinically relevant. Evidence has suggested that the coadministration of H 1 -antihistamines with certain agents, including medications, herbal products, and foods, results in the inhibition of metabolism and thereby accumulation of these agents. For the first-generation antihistamines that have a narrow therapeutic index, such increases in plasma concentrations are associated with an increased risk of adverse effects, such as sedation and even cardiotoxicity. 20 Notably, differences exist among antihistamines because of variations in their metabolic profile, ranging from those that exhibit significant interactions with the hepatic cytochrome P450 isoenzymes (such as astemizole and terfenadine) to those that are practically devoid of interactions in the P450 system (such as cetirizine, fexofenadine, or levocetirizine). In order to assess the clinical relevance of such drug-drug interactions, evaluation of the therapeutic index is particularly important. As described below, for those antihistamines that exhibit a broad therapeutic index, although such interactions may alter the plasma H 1 -antihistamine concentration, this is unlikely to translate into relevant changes in clinical outcomes. THE CLINICAL SIGNIFICANCE OF A WIDE THERAPEUTIC INDEX Fexofenadine is an example of an H 1 -antihistamine that has an extremely broad therapeutic index beyond the recommended daily dose of 120 to 180 mg. In clinical studies, the minimally effective dose of fexofenadine is 20 mg twice daily, and even when administered at doses of 360 mg, 2 to 3 times the usual recommended total daily dose, fexofenadine does not cause CNS effects as assessed using objective testing. 14 Furthermore, when doses of 690 mg twice daily, 6 times the recommended daily dose, were given in clinical studies, fexofenadine was not associated with subjective sedation, and steady-state plasma concentrations of up to 4900 ng/ml were shown to be well tolerated. 13,18 Investigations have also shown that fexofenadine does not cause cardiovascular effects: single (up to 800 mg daily) or multiple (up to 690 mg twice daily for a period of 28 days) doses of fexofenadine administered to healthy individuals produced no clinically significant changes in cardiac conductance. 12 A broad therapeutic index is valuable for an H 1 - antihistamine, not only in terms of potential effects of drug-drug interactions but also in situations where overcompliance occurs; that is, when patients increase their H 1 -antihistamine dose in order to obtain symptom relief. For drugs with a broad therapeutic index, even if the recommended dose is exceeded, the patient is unlikely to be at risk from adverse effects. Evaluation of the therapeutic index is also important given the recent interest in the potential use of antihistamines in the treatment of asthma. In many of the clinical studies that have demonstrated the relief of asthma symptoms, H 1 -antihistamines have been given in higher doses than those used in the treatment of allergic rhinitis. 21 Therefore, an antihistamine with a broad therapeutic index offers greater potential in terms of flexible dosing for the treatment of other allergic diseases, such as asthma, compared with a drug that has a narrow therapeutic index. CONCLUSION Analysis of the efficacy and safety of antihistamines is essential for determining the therapeutic index of these agents, and this is a more appropriate measure than considering either efficacy or safety alone. Because secondgeneration antihistamines have demonstrated significant efficacy in clinical studies, their therapeutic indices are determined primarily by safety considerations. Fexofenadine is an example of an antihistamine with a wide therapeutic index, offering potential flexibility of dosing without increased safety concerns. In the future, evaluating the therapeutic index for all antihistamines in various patient populations will be important so that these agents can be optimally prescribed. Advanced Studies in Medicine 875
5 REFERENCES 1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287(3): Simons FE, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol. 2001;107(3): Grant AJ, Danielson L, Rihoux J-P, DeVos C. A comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo in suppressing the cutaneous response to histamine. Int Arch Allergy Immunol.1999;118: Lee EE, Maibach HI. Treatment of urticaria. An evidencebased evaluation of antihistamines. Am J Clin Dermatol. 2001;2(1): Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999;36(5): Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30(6): Casale TB, Andrade C, Qu R. Safety and efficacy of oncedaily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc. 1999;20(3): Howarth P, Stern M, Roi L, Reynolds R, Bousquet JP. Doubleblind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 mg and 180 mg once-daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol.1999;104(5): Finn A, Kaplan A, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104(5): Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other sideeffects. Clin Exp Allergy. 1999;29(suppl 3): Mann R, Pearce G, Dunn N, Shakir S. Sedation with nonsedating antihistamines: four prescription-event monitoring studies in general practise. BMJ. 2000;320: Pratt C, Brown A, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(3): Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(3): Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy. 2002;32(1): Dogan A, Offord S, Catafau A, et al. Cerebral H1-receptor pattern at baseline and after a single oral dose of the antihistamine fexofenadine [abstract]. Ann Allergy Asthma Immunol. 2000;86(1):108. Abstract P Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4): Zareba W, Moss AJ, Rosero SZ, et al. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol. 1997;80(9): Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther. 1998;64(6): Hansten PD, Levy RH. Role of P-glycoprotein and organic anion transporting polypeptides in drug absorption and distribution: focus on H1-receptor antagonists. Clin Drug Invest. 2001;21(8): Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol.1996;36: Simons FE. Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma? Clin Exp Allergy. 1999;29(suppl 3): Vol. 2, No. 24 November 2002
More than 6 decades have passed since
THE CONCEPT OF THE THERAPEUTIC WINDOW IN THE CHOICE OF H 1 -RECEPTOR ANTAGONIST * Peter H. Howarth, DM, FRCP ABSTRACT Antihistamines have existed for more than 60 years. The first-generation antihistamines
More informationVOLUME 89, SEPTEMBER,
Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges Juan Gispert, MD*; Rosa Antonijoan, PhD ; Manel Barbanoj, PhD ; Ignaci Gich, PhD ; Estrella Garcia, PhD*; Ramon Esbrí,
More informationEffects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses
Experimental dermatology Original article Effects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses D. Bayramgürler, N. Bilen, R. Apaydýn, L. Altıntaş,* G. Sal, Ş.
More informationAntihistamines: a brief review
Antihistamines: a brief review Van Schoor J, MPharm Amayeza Info Centre Introduction The prevalence rates of allergic diseases such as allergic rhinitis and asthma appear to be increasing in many countries.
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 4 April 2001 A The second-generation (peripherally-selective)
More informationFirst do no harm: Managing antihistamine impairment in patients with allergic rhinitis
First do no harm: Managing antihistamine impairment in patients with allergic rhinitis The Antihistamine Impairment Roundtable: Thomas B. Casale, MD, a Michael S. Blaiss, MD, b Erwin Gelfand, MD, c Timothy
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More informationPOSTER PRESENTATIONS
POSTER PRESENTATIONS POSTER PRESENTATIONS The following are summaries of posters presented at the XXI Congress of the European Academy of Allergology and Clinical Immunology, Naples, Italy, June1-5, 2002.
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationP Usharani, DNB, MD MUR Naidu, MD KLN Reddy, PhD * BPS Reddy, PhD * T Ramesh Kumar, MD
Randomized, Double-Blind, Crossover Comparison Between Two Levocetirizine Formulations on Histamine-Induced Cutaneous Response in Healthy Male Human Adult Volunteers P Usharani, DNB, MD MUR Naidu, MD KLN
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationEvaluation of Efficacy and Sedative Profiles of H1 Antihistamines by Large-Scale Surveillance Using the Visual Analogue Scale (VAS)
Allergology International. ;57:57-63 DOI:.33allergolint.O-7-55 ORIGINAL ARTICLE Evaluation of Efficacy and Sedative Profiles of H Antihistamines by Large-Scale Surveillance Using the Visual Analogue Scale
More informationReview Article Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria
BioMed Research International Volume 2013, Article ID 626837, 6 pages http://dx.doi.org/10.1155/2013/626837 Review Article : A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationMTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride
MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationClinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines
TCP 2014;22(1):13-18 http://dx.doi.org/10.12793/tcp.2014.22.1.13 Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More informationbenzene acetic acid, 4-[1-hydroxy-4-[4-(hydroxy diphenylmethyl)-1- piperidinyl]butyl]-a,a-dimethyl-, hydrochloride
XERGIC Fexofenadine hydrochloride PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: fexofenadine hydrochloride benzene acetic acid, 4-[1-hydroxy-4-[4-(hydroxy diphenylmethyl)-1-
More informationThe management of chronic urticaria in primary care for adults and children
The management of chronic urticaria in primary care for adults and children September Version 2.0 This supersedes version 1.0 Review due in September 2019 Document location DOCUMENT CONTROL Copies of this
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationFexofenadine apollo
Fexofenadine apollo +9191 46 950 950 Fexofenadine apollo +9191 46 950 950 Fexofenadine CAS Number : 83799-24-0 Molecular Weight : 501.65 g/mol Molecular Formula : C32H39NO4 Systematic (IUPAC) : 2-(4-{1-hydroxy-4-[4-
More informationEbastine in allergic rhinitis and chronic idiopathic urticaria
Allergy 2008: 63 (Suppl. 89): 1 20 Ó 2008 The Author Journal compilation Ó 2008 Blackwell Munksgaard ALLERGY Review article Ebastine in allergic rhinitis and chronic idiopathic urticaria Histamine is a
More informationBilastine in allergic rhinoconjunctivitis and urticaria
Allergy REVIEW ARTICLE C. Bachert 1, P. Kuna 2 & T. Zuberbier 3 1 Department of Otorhinolaryngology, University Hospital Ghent, Ghent, Belgium; 2 Division of Internal Medicine, Asthma and Allergy, Berlicki
More informationAllergy and Immunology Review Corner: Chapter 87 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al.
Allergy and Immunology Review Corner: Chapter 87 of Middleton s Allergy Principles and Practice, 7 th Edition, edited by N. Franklin Adkinson, et al. Chapter 87: Histamine and H-1 Anti-Histamines Prepared
More informationantihistamines A del Cuvillo 1, J Mullol 2, J Bartra 3, I Dávila 4, I Jáuregui 5, J Montoro 6, J Sastre 7, AL Valero 3
Comparative pharmacology of the H 1 Comparative pharmacology of the H 1 A del Cuvillo 1, J Mullol 2, J Bartra 3, I Dávila 4, I Jáuregui 5, J Montoro 6, J Sastre 7, AL Valero 3 1 Clínica Dr. Lobatón, Cádiz,
More informationAllergic Rhinitis. Abstract Allergic rhinitis is defined as an immunologic response moderated by IgE and is. Continuing Education Column
Allergic Rhinitis Hun Jong Dhong, M.D. Department of Otorhinolaryngology Head and Neck Surgery Sungkyunkwan University School of Medicine, Samsung Medical Center E mail : hjdhong@smc.samsung.co.kr Abstract
More informationANTIHISTAMINES ARE widely used to treat allergic. Desloratadine Shows No Effect on Performance During 6 h at 8,000 ft Simulated Cabin Altitude
RESEARCH ARTICLE Desloratadine Shows No Effect on Performance During 6 h at 8,000 ft Simulated Cabin Altitude Pierre J. L. Valk, Dominique B. Van Roon, Ries M. Simons, and Ger Rikken VALK PJL, VAN ROON
More informationDrug Class Review Newer Antihistamines
Drug Class Review Newer Antihistamines Final Report Update 2 May 2010 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs.
More informationDoes Desloratadine Alter the Serum Levels of Montelukast When Administered in a Fixed-Dose Combination?
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Does Desloratadine Alter the Serum Levels of Montelukast When Administered in a Fixed-Dose Combination? Cemal
More informationDrug Effectiveness Review Project Literature Scan Summary. Month/Year of Review: January 2015 Date of Last Review: January 2013
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights
More informationARIA. At-A-Glance Pocket Reference 2007
ARIA_Glance_2007_8pg:ARIA_Glance_English 9/14/07 3:10 PM Page 1 ARIA At-A-Glance Pocket Reference 2007 1 st Edition NEW ARIA UPDATE BASED ON THE ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA WORKSHOP REPORT
More informationPRODUCT INFORMATION TELFAST. Chemical Structure Fexofenadine HCl is an equimolar mixture of two enantiomers. structure:
NAME OF THE MEDICINE Non-proprietary Name Fexofenadine (as hydrochloride). PRODUCT INFORMATION TELFAST Chemical Structure Fexofenadine HCl is an equimolar mixture of two enantiomers. structure: It has
More informationManagement of Chronic Idiopathic Urticaria
9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic
More informationPRODUCT MONOGRAPH. ALLEGRA 12 Hour. (fexofenadine hydrochloride, Manufacturer s standard) 60 mg Tablets. ALLEGRA 24 Hour
PRODUCT MONOGRAPH ALLEGRA 12 Hour (fexofenadine hydrochloride, Manufacturer s standard) 60 mg Tablets ALLEGRA 24 Hour (fexofenadine hydrochloride, Manufacturer s standard) 120 mg Tablets Histamine H 1
More informationCompared with older compounds of this class of drugs, the newer, secondgeneration
Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults Pierre Gehanno, MD*; Clothilde Bremard-Oury, MD ; and Philippe Zeisser, MD Background: Second-generation histamine H 1 -receptor
More information!"#$% &!'(') *!'+ $&,"-.&% / 01 )2% % 6!( 78
() 8 185 14-19 :!"#$% &!'(') *!'+ $&,"-.&% / 01 )% 4 454 +% 6!( 78 %(" /' M.D. M.D. M.D. M.D. M.Sc.!" * 1 Ph.D.. %)'% * %)F *'"G"6.F9"< " ($) *.A,:0-&E= *(D@)...% /" :6(= >4?@ AB0% * :/9: ; < 85/10/19
More informationCME INFORMATION. December 16, 2002 THE AMERICAN JOURNAL OF MEDICINE Volume 113 (9A) 55S
CME SECTION Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), UMDNJ New Jersey Medical School, Department of Medicine, Division of Allergy and Immunology, and the UMDNJ Center
More informationPredicting which medication classes interfere with allergy skin testing
Predicting which medication classes interfere with allergy skin testing Kunal M. Shah, M.D, 1 Matthew A. Rank, M.D., 1 Shoban A. Davé, M.D., 2 Corrine L. Oslie, R.N., 1 and Joseph H. Butterfield, M.D.
More informationComparing the Inhibitory Effects of Diphenhydramine Hydrochloride with Cetirizine Dihydrochloride on Isolated Trachea of Rabbit
ORIGINAL ARTICLE Comparing the Inhibitory Effects of Diphenhydramine Hydrochloride with Cetirizine Dihydrochloride on Isolated Trachea of Rabbit GULSHAN ARA JALBANI 1, MADIHA SHAH 2, MANZOOR AHMED UNAR
More informationEfficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis
Human Journals Research Article July 2018 Vol.:10, Issue:1 All rights are reserved by Manju K Mathew et al. Efficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis Keywords:
More informationPharmacotherapy for Allergic Rhinitis
Pharmacotherapy for Allergic Rhinitis William Reisacher, MD FACS FAAOA Assistant Professor Weill Cornell Medical College The Impact of Allergic Rhinitis Allergic rhinitis affects approximately 50 million
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 10 mg of cetirizine dihydrochloride.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin STADA 10 mg, film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg of cetirizine
More informationThe effects of antihistamines on cognition and performance
The effects of antihistamines on cognition and performance Gary G. Kay, PhD Washington, DC Allergic diseases are responsible for substantially more disability than is generally realized. Allergic rhinitis
More informationLatest advances in the management of childhood allergic rhinitis
Latest advances in the management of childhood allergic rhinitis Jason Y K Chan Assistant Professor Department of Otorhinolaryngology, Head & Neck Surgery The Chinese University of Hong Kong Disclosures
More informationIdeal Sedative Agent. Pharmacokinetics. Benzodiazepines. Pharmacodynamics 11/11/2013
Ideal Sedative Agent Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry Peter Walker Anxiolysis Analgesic No effect on CVS No effect on respiratory system Not metabolised Easy and
More informationIdeal Sedative Agent. Benzodiazepines 11/12/2013. Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry.
Pharmacology of Benzodiazepines Used for Conscious Sedation in Dentistry Peter Walker Ideal Sedative Agent Anxiolysis Analgesic No effect on CVS No effect on respiratory system Not metabolised Easy and
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME Telfast 6 11 years 30mg film coated tablets # Telfast 60mg film coated tablets Telfast 120mg film coated tablets Telfast 180mg film coated tablets Telfast Oral Liquid,
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationDOSAGE FORMS AND STRENGTHS CLARINEX Tablets - 5 mg (3) CLARINEX Oral Solution - 0.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CLARINEX safely and effectively. See full prescribing information for CLARINEX. CLARINEX (desloratadine)
More informationDrug Class Review Newer Antihistamines
Drug Class Review Newer Antihistamines Preliminary Scan Report 1 Update 3 November 2012 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms
More informationAllergic rhinitis is a frequent chronic disease that may. Persistent Allergic Rhinitis and the XPERT Study SYMPOSIUM REPORT SUPPLEMENT
SYMPOSIUM REPORT SUPPLEMENT Persistent Allergic Rhinitis and the XPERT Study Anthi Rogkakou, MD, Elisa Villa, MD, Valentina Garelli, MD, G. Walter Canonica, MD Abstract: Allergic rhinitis (AR) is a chronic
More informationOpinion 8 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 8 January 2014 WYSTAMM 1 mg/ml, oral solution 120 ml vial with syringe for oral administration (CIP: 34009 222 560
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Aerius 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. For a
More informationMontelukast: a better alternative than antihistaminics in allergic rhinitis
International Journal of Otorhinolaryngology and Head and Neck Surgery Kaur G et al. Int J Otorhinolaryngol Head Neck Surg. 017 Apr;():17- http://www.ijorl.com pissn -99 eissn -97 Original Research Article
More informationPage 1 of 9. Revised: 09/2012 FULL PRESCRIBING INFORMATION: CONTENTS *
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XYZAL safely and effectively. See full prescribing information for XYZAL. XYZAL (levocetirizine dihydrochloride)
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationPackage Insert. Clistin Dry. 24 hours.
Package Insert Clistin Dry Product Summary 1. Name of the medicinal product Clistin Dry 2. Qualitative and quantitative composition Dextromethorphan Hbr 10 mg Chlorpheniramine Maleate 2 mg Phenylephrine
More informationOther sources of information
1.1. Fexofenadine and Fexofenadine hydrochloride is a non-sedating H 1 antihistamine. It was registered in the Netherlands in 1997. Fexofenadine is indicated for the relief of symptoms associated with
More informationPRINCIPAL MEDICATION OPTIONS FOR RHINITIS
SEE INDICATED SUMMARY STATEMENT (SS#) DISCUSSION FOR SUPPORTING DATA ALLERGIC RHINITIS (AR): SEASONAL (SAR) AND PERENNIAL (PAR) MONOTHERAPY ORAL Antihistamines, oral (H1 receptor antagonists) (SS# 61-64)
More informationVI.B.2 Elements for a public summary
VI.B.2 Elements for a public summary VI.B.2.1 Overview of disease epidemiology Fexofenadine hydrochloride is a non-sedating H 1 -antihistamine. [Fexofenadine] 180mg filmcoated tablets are indicated for
More informationAn Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence
More informationDrug Class Review. Newer Antihistamines
Drug Class Review Newer Antihistamines Preliminary Scan Report #3 February 2015 Last Report: Update #2, May 2010 The purpose of reports is to make available information regarding the comparative clinical
More informationLIVOSTIN Eye Drops and Nasal Spray
LIVOSTIN Eye Drops and Nasal Spray PRODUCT INFORMATION NAME OF DRUG Levocabastine hydrochloride DESCRIPTION Levocabastine, (-)-[3S-[1(cis), 3 alpha, 4 beta]]-1-[4-cyano-4-(4-fluorophenyl) cyclohexyl]-3-
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationOphthalmic Antihistamine Step Therapy Program Summary
Ophthalmic Antihistamine Step Therapy Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-8 Drug FDA Indication(s) Administration and Dosing Bepreve Treatment of itching associated Instill one drop into
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin Mylan 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of cetirizine
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cetec 10 mg film-coated tablets allacan TM 10mg film-coated tablets Health Essentials Hayfever and allergy Relief 10mg film-coated tablets
More informationPRODUCT INFORMATION ZYRTEC LEVOCABASTINE Eye Drops and Nasal Spray
PRODUCT INFORMATION ZYRTEC LEVOCABASTINE Eye Drops and Nasal Spray NAME OF MEDICINE Levocabastine hydrochloride DESCRIPTION Levocabastine, (-)-[3S-[1(cis), 3 alpha, 4 beta]]-1-[4-cyano-4-(4-fluorophenyl)
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationCLASSIFICATION OF SEDATING ANTIHISTAMINES
CLASSIFICATION OF SEDATING ANTIHISTAMINES TASK To examine the safety of sedating antihistamines and produce a report suggesting the most appropriate schedule for both combination and single ingredient
More informationDefense Technical Information Center Compilation Part Notice
UNCLASSIFIED Defense Technical Information Center Compilation Part Notice ADPO 11043 TITLE: Hr-Antihistamines and Aircrew DISTRIBUTION: Approved for public release, distribution unlimited This paper is
More informationLevocetirizine dihydrochloride
Levocetirizine dihydrochloride Xyzal Oral Preparations PRODUCT DESCRIPTION Each film-coated tablet of Levocetirizine dihydrochloride (Xyzal ) contains 5 mg of levocetirizine. Each ml of Levocetirizine
More informationClinical comparison of histamine H -receptor antagonist drugs
Clinical comparison of histamine H -receptor antagonist drugs Lawrence M. Du Buske, MD Fitchburg, Mass. Nearly 40 million Americans have symptoms of upper respiratory alleigies, making antihistamines among
More informationDiphenhydramine (Benadryl) Adam Nasir Corrigan Horton
Diphenhydramine (Benadryl) Adam Nasir Corrigan Horton Main Points Diphenhydramine acts as an inverse agonist at its molecular target of action, the H 1 - Histamine receptors Early stages of hypersensitivity
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Aerius 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. Excipient(s)
More informationC O N F I D E N T I A L
1. NAME OF THE MEDICINAL PRODUCT Lacinet 10 mg, orodispergeerbare tabletten Lacinet 20 mg, orodispergeerbare tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each orodispersible tablet contains 10
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory LONGCET. Levocetirizine Dihydrochloride Tablets IP 5 mg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory LONGCET Levocetirizine Dihydrochloride Tablets IP 5 mg QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationFormat. Allergic Rhinitis Optimising Mananagement. Degree of Quality of life Restriction in the Allergic Patient. The allergy epidemic:
Format Allergic Rhinitis Optimising Mananagement Dr Dominic Mallon FRACP FRCPA Clinical Immunologist and Allergist Fiona Stanley Hospital Impact of allergic rhinitis Diagnosis and management of allergic
More informationCLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN GERIATRICS *)
3CC9a CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN GERIATRICS *) Guideline Title Clinical Investigation of Medicinal Products in Geriatrics*) Legislative basis Directive 75/318/EEC, as amended Date
More informationClinical Policy: Antihistamines Reference Number: CP.HNMC.18 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.HNMC.18 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationF/P F/P VAS. 2 fexofenadine pseudoefedrine F/P F/P F/P. dust mite HDM 17. fexofenadine pseudoefedrine F/P F/P
JJIAO 35 1 : 1 6, 2017 原 著 / 1 1 2 1 1 3 1 2 3 NPO 2 fexofenadine pseudoefedrine F/P F/P 17 12 5 28.6 F/P F/P VAS F/P 8 30 90 8 2 6 8 F/P F/P, fexofenadine/pseudoephedrine; VAS, visual analogue scale 2
More informationAcute urticaria in children - management. Clive Grattan St John s Institute of Dermatology, London Norfolk & Norwich University Hospital
Acute urticaria in children - management Clive Grattan St John s Institute of Dermatology, London Norfolk & Norwich University Hospital Scope of my talk What is acute urticaria? Who, why, when and where?
More informationGeriatric Pharmacology
Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological
More informationComparing the Effects of Diphenhydramine Hydrochloride with Loratadine on Isolated Trachea of Rabbit
ORIGINAL ARTIC Comparing the Effects of Diphenhydramine Hydrochloride with Loratadine on Isolated Trachea of Rabbit MANZOOR AHMED UNAR, GULSHAN ARA JALBANI*, SHAH MURAD**, MADIHA SHAH* ABSTRACT Objective:
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationXolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.
Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012
Drug, Treatment, Device name Omalizumab (Xolair; Novartis) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by North Lincolnshire CCG November 2012 Licensed indication Omalizumab
More informationEli O. Meltzer, MD, a John M. Weiler, MD, b and Michael D. Widlitz, MD c
Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, Ioratadine, and placebo for seasonal allergic rhinitis Eli O. Meltzer, MD, a John M. Weiler, MD, b and
More informationIce Cube Test in Children with Cold Urticaria
Asian Pacific Journal of Allergy and Immunology (1 992) 10.' 111 115 Ice Cube Test in Children with Cold Urticaria Nualanong Visitsuntorn, Montri Tuchinda, Napa Arunyanark and Sirikul Kerdsomnuk Cold urticaria
More informationPackage Insert. Clistin Wet
Package Insert Clistin Wet Product Summary 1. Name of the medicinal product Clistin Wet 2. Qualitative and quantitative composition Levocetirizine Hydrochloride 2.5 mg Ambroxol Hydrochloride 30 mg Guaiphenesin
More informationEU RISK MANAGEMENT PLAN (EU-RMP)
EU RISK MANAGEMENT PLAN (EU-RMP) HYDROXYZINE 25 mg, scored film-coated tablets Active substance(s) (INN or common name): Hydroxyzine hydrochloride Pharmaco-therapeutic group (ATC Code): N05BB01, Anxiolytics
More information